229 related articles for article (PubMed ID: 9694506)
1. Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer: a redox-mediated mechanism for demand-induced hematopoietic regulation.
Paukovits WR; Paukovits JB; Moser MH; Konstantinov S; Schulte-Hermann R
Exp Hematol; 1998 Aug; 26(9):851-8. PubMed ID: 9694506
[TBL] [Abstract][Full Text] [Related]
2. Hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys: a new synthetic derivative for avoiding dimerization and loss of inhibitory activity.
Paukovits WR; Hergl A; Schulte-Hermann R
Mol Pharmacol; 1990 Sep; 38(3):401-9. PubMed ID: 2402229
[TBL] [Abstract][Full Text] [Related]
3. Protection from arabinofuranosylcytosine and n-mustard-induced myelotoxicity using hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys monomer and dimer.
Paukovits WR; Moser MH; Binder KA; Paukovits JB
Blood; 1991 Mar; 77(6):1313-9. PubMed ID: 2001454
[TBL] [Abstract][Full Text] [Related]
4. The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors.
Paukovits JB; Rutter R; Ganglberger E; Karlic HI; Marian B; Paukovits WR
Mol Pharmacol; 1999 Oct; 56(4):665-74. PubMed ID: 10496948
[TBL] [Abstract][Full Text] [Related]
5. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.
Paukovits WR; Moser MH; Binder KA; Paukovits JB
Cancer Treat Rev; 1990 Sep; 17(2-3):347-54. PubMed ID: 2272050
[TBL] [Abstract][Full Text] [Related]
6. Stem cell stimulation in vitro by the dekapeptide (pEEDCK)2: a single-factor alternative for multifactor cocktails.
Paukovits JB; Paukovits WR
Leukemia; 1995 Oct; 9 Suppl 1():S48-52. PubMed ID: 7475313
[TBL] [Abstract][Full Text] [Related]
7. Effect of the hemoregulatory peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1alpha is reduced in bone marrow cultures from patients with chronic myeloid leukemia (CML).
Karlic H; Louda N; Pfeilstöcker M; Keil F; Lohninger A; Pittermann E; Paukovits J
Stem Cells; 2001; 19(4):321-8. PubMed ID: 11463952
[TBL] [Abstract][Full Text] [Related]
8. Suppressive biological activity of a synthetic pentapeptide on highly enriched human and murine marrow hematopoietic progenitors: synergism with recombinant human tumor necrosis factor-alpha and interferon-gamma.
Lu L; Foa P; Chillemi F; Shen RN; Lin ZH; Carow C; Broxmeyer HE
Exp Hematol; 1989 Oct; 17(9):935-41. PubMed ID: 2506072
[TBL] [Abstract][Full Text] [Related]
9. Pre-CFU-S quiescence and stem cell exhaustion after cytostatic drug treatment: protective effects of the inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK).
Paukovits WR; Moser MH; Paukovits JB
Blood; 1993 Apr; 81(7):1755-61. PubMed ID: 8461461
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of a synthetic pentapeptide on hemopoietic stem cells in vitro and in vivo.
Laerum OD; Paukovits WR
Exp Hematol; 1984 Jan; 12(1):7-17. PubMed ID: 6230248
[TBL] [Abstract][Full Text] [Related]
11. In vivo modulation of hematopoiesis by a novel hematoregulatory peptide.
Pelus LM; King AG; Broxmeyer HE; DeMarsh PL; Petteway SR; Bhatnagar PK
Exp Hematol; 1994 Mar; 22(3):239-47. PubMed ID: 8112423
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hematotoxic side effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide.
Paukovits WR; Guigon M; Binder KA; Hergl A; Laerum OD; Schulte-Hermann R
Cancer Res; 1990 Jan; 50(2):328-32. PubMed ID: 2295072
[TBL] [Abstract][Full Text] [Related]
13. Regulation of colony-stimulating activity production from bone marrow stromal cells by the hematoregulatory peptide, HP-5.
King AG; Talmadge JE; Badger AM; Pelus LM
Exp Hematol; 1992 Feb; 20(2):223-8. PubMed ID: 1544391
[TBL] [Abstract][Full Text] [Related]
14. The dimer of hemoregulatory peptide (HP5B) stimulates mouse and human myelopoiesis in vitro.
Laerum OD; Sletvold O; Bjerknes R; Eriksen JA; Johansen JH; Schanche JS; Tveterås T; Paukovits WR
Exp Hematol; 1988 May; 16(4):274-80. PubMed ID: 3258825
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of enriched stem cells in vivo and in vitro by the hemoregulatory peptide SK&F108636.
Veiby OP; LoCastro S; Bhatnagar P; Olsen WM
Stem Cells; 1996 Mar; 14(2):215-24. PubMed ID: 8991541
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory peptides in hematopoiesis.
Guigon M; Bonnet D
Exp Hematol; 1995 Jun; 23(6):477-81. PubMed ID: 7768302
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hematopoietic stem cell proliferation by hemoregulatory peptide pyroGlu-Glu-Asp-Cys-Lys (pEEDCK) provides protection against short-term neutropenia and long-term damage.
Paukovits WR; Moser MH; Rutter R; Paukovits JB
Ann N Y Acad Sci; 1991; 628():92-104. PubMed ID: 2069326
[No Abstract] [Full Text] [Related]
18. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
Wierenga PK; Konings AW
Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro effects of cytokines and the hemoregulatory peptide dimer (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 on G alpha16-positive hematopoiesis.
Pfeilstöcker M; Karlic H; Paukovits J; Anzenberger G; Louda N; Salamon J; Mühlberger H; Strobl H; Pittermann E; Heinz R
Leukemia; 1999 Apr; 13(4):590-4. PubMed ID: 10214866
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-Ser-Asp-Lys-Pro.
Lenfant M; Itoh K; Sakoda H; Sotty D; Sasaki NA; Wdzieczak-Bakala J; Mori KJ
Exp Hematol; 1989 Sep; 17(8):898-902. PubMed ID: 2767182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
